Home LiteratureArticle Details

PMID: 2138064 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.

Cancer chemotherapy and pharmacology ·Vol. 25 ·No. 6 ·1990-00-00 ·Pages 449-53

Viner CV, Selby PJ, Zulian GB, Gore ME, Butcher ME, Wootton CM, McElwain TJ

Abstract

A total of 33 patients with myeloma receiving treatment with high-dose melphalan (140-200 mg/m2 i.v.) were given the 5HT3 antagonist Ondansetron (Glaxo) as an antiemetic. In 42% of patients, emetic episodes were either abolished (15%) or reduced to two or less (27%). Efficacy was not related to scheduling (two regimens) or total dose. No sedative or other significant side effects were seen. Ondansetron is a highly effective non-sedative antiemetic that justifies further assessment in combination with other antiemetics in patients receiving cytotoxic drugs associated with the production of severe nausea and vomiting.

MeSH Terms

Administration, Oral Antiemetics/administration & dosage,pharmacokinetics,therapeutic use Drug Administration Schedule Drug Evaluation Female Humans Imidazoles/administration & dosage,pharmacokinetics,therapeutic use Infusions, Intravenous Male Melphalan/administration & dosage,adverse effects Middle Aged Multiple Myeloma/blood,drug therapy Nausea/chemically induced,prevention & control Ondansetron Serotonin Antagonists Vomiting/chemically induced,prevention & control

Chemicals

Antiemetics Imidazoles Serotonin Antagonists Ondansetron Melphalan

Authors & Affiliations

7 authors, click to expand affiliations / ORCID

Viner C V

Section of Medicine, Institute of Cancer Research, Sutton, Surrey, UK.

Selby P J

Zulian G B

Gore M E

Butcher M E

Wootton C M

McElwain T J

References (11)

11 references, click to expand

Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.
Lancet. 1987 Jun 27;1(8548):1461-3 PMID: 2885454
High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.
Lancet. 1983 Oct 8;2(8354):822-4 PMID: 6137651
High-dose melphalan and autologous bone marrow transplant as treatment for refractory Hodgkin's disease.
J Clin Oncol. 1986 Apr;4(4):612 PMID: 3514810
Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.
J Clin Oncol. 1988 Apr;6(4):659-62 PMID: 2965755
Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin.
J Natl Cancer Inst. 1989 Jan 4;81(1):42-6 PMID: 2521184
Multiple myeloma treated with high dose intravenous melphalan.
Br J Haematol. 1987 May;66(1):55-62 PMID: 3593657
Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist.
Br J Cancer. 1988 Nov;58(5):651-3 PMID: 2851312
Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission.
Bone Marrow Transplant. 1988 Jan;3(1):21-9 PMID: 3048467
The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting.
Eur J Cancer Clin Oncol. 1988 Aug;24(8):1383-4 PMID: 2972545
High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma.
Exp Hematol. 1979;7 Suppl 5:360-71 PMID: 400698
The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.
Br J Cancer. 1988 Nov;58(5):644-50 PMID: 2851311

Article Info

Journal

Cancer chemotherapy and pharmacology

Abbr.

Cancer Chemother Pharmacol

ISSN

0344-5704

DOI

10.1007/BF00686058

Published

1990-00-00

Pages

449-53

Language

English

Region

Germany

NLM ID

7806519

Subset

External Links

PubMed source DOI: 10.1007/BF00686058 View journal details

Analysis Services

Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.

Contact

WeChat Official Account